(CANCER HEMATOPOIESIS AND IMMUNOLOGY) The mission of Cancer Hematopoiesis and Immunology (CHI) Program is hewed to the tenet of collaborative transdisciplinary research that is aligned with the UMCCC strategic research priorities. Members of the CHI Program are committed to the pursuit of research that defines the fundamental roles of immune and non- immune hematopoietic cells in cancer as well as post-transplantation therapies. Working under the broad theme of cellular and innate immunity, normal and malignant hematopoiesis, and hematopoietic stem cell transplantation biology, the CHI Program seeks to develop translational approaches that will improve hematopoietic cell transplantation (HCT) outcomes and hasten the development of novel vaccination strategies. Toward these goals, the CHI Program is a diverse, interdisciplinary research group comprised of 24 members from 10 departments within three University of Michigan schools/colleges. The CHI Program has $10.3M in annual direct funding (88% peer-reviewed), with $2.7M from the NCI, $5.3M from other NIH sources and $2.3M in additional support. During the past project period, the Program generated 376 publications, including high impact reports appearing in Cell, Nature, Science, NEJM, and the JCI. The CHI Program enjoys strong interactions with other UMCCC members, underlined by 24% of their publications arising from intra- programmatic efforts and 43% from inter-programmatic collaborations. To build on these advances, Program aims include: 1) elucidate molecular mechanisms regulating normal immune/non-immune hematopoietic cell function during homeostasis and their alterations in cancer and HCT, 2) characterize the role of the tissue microenvironment in controlling the function and regulation of immune cells in cancer, hematopoiesis and HCT and 3) define key concepts, approaches, and reagents in preclinical studies to translate the most compelling advances into the clinic via collaboration with the Translational and Clinical Research (TACR) Program. As such, CHI Program members support the UMCCC mission by performing state-of-the-art research underlying both major and less common cancer types within our catchment area, while training the next generation of cancer researchers, and promoting collaboration with other UMCCC Programs and beyond.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Michigan Ann Arbor
Ann Arbor
United States
Zip Code
Jiagge, Evelyn; Jibril, Aisha Souleiman; Davis, Melissa et al. (2018) Androgen Receptor and ALDH1 Expression Among Internationally Diverse Patient Populations. J Glob Oncol :1-8
Bowers, Emily; Slaughter, Anastasiya; Frenette, Paul S et al. (2018) Granulocyte-derived TNF? promotes vascular and hematopoietic regeneration in the bone marrow. Nat Med 24:95-102
Holt, Melissa C; Assar, Zahra; Beheshti Zavareh, Reza et al. (2018) Biochemical Characterization and Structure-Based Mutational Analysis Provide Insight into the Binding and Mechanism of Action of Novel Aspartate Aminotransferase Inhibitors. Biochemistry 57:6604-6614
Wang, Yin; Day, Mark L; Simeone, Diane M et al. (2018) 3-D Cell Culture System for Studying Invasion and Evaluating Therapeutics in Bladder Cancer. J Vis Exp :
Suresh, Krithika; Owen, Dawn; Bazzi, Latifa et al. (2018) Using Indocyanine Green Extraction to Predict Liver Function After Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys 100:131-137
O'Dwyer, David N; Zhou, Xiaofeng; Wilke, Carol A et al. (2018) Lung Dysbiosis, Inflammation, and Injury in Hematopoietic Cell Transplantation. Am J Respir Crit Care Med 198:1312-1321
El Kadi, Najwa; Wang, Luo; Davis, April et al. (2018) The EGFR T790M Mutation Is Acquired through AICDA-Mediated Deamination of 5-Methylcytosine following TKI Treatment in Lung Cancer. Cancer Res 78:6728-6735
Feng, Mary; Suresh, Krithika; Schipper, Matthew J et al. (2018) Individualized Adaptive Stereotactic Body Radiotherapy for Liver Tumors in Patients at High Risk for Liver Damage: A Phase 2 Clinical Trial. JAMA Oncol 4:40-47
Xiong, Yi; Torsoni, Adriana Souza; Wu, Feihua et al. (2018) Hepatic NF-kB-inducing kinase (NIK) suppresses mouse liver regeneration in acute and chronic liver diseases. Elife 7:
Eisenberg, Marisa C; Campredon, Lora P; Brouwer, Andrew F et al. (2018) Dynamics and Determinants of HPV Infection: The Michigan HPV and Oropharyngeal Cancer (M-HOC) Study. BMJ Open 8:e021618

Showing the most recent 10 out of 1493 publications